This trial is active, not recruiting.

Condition primary progressive multiple sclerosis
Treatment generation of 'omic markers of disease progression
Sponsor Duke University
Start date January 2013
End date February 2020
Trial size 100 participants
Trial identifier NCT01776060, Pro00040961


The goal of this study is to enroll 100 participants with Primary Progressive Multiple Sclerosis (PPMS) that have joined the MURDOCK Study Horizon 1.5 (Duke IRB Pro00011196) and the Multiple Sclerosis cohort (Duke IRB Pro00023791). All 100 participants will complete a biannual collection of a follow up questionnaire and blood/urine collection for a period of 5 years.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective other

Primary Outcomes

Generation of 'omic markers of disease progression
time frame: 5 years

Eligibility Criteria

All participants from 18 years up to 100 years old.

Inclusion Criteria: - Enrolled in the MURDOCK Study Horizon 1.5 (Pro00011196) - Enrolled in the Multiple Sclerosis Cohort (Pro00023791) - Diagnosed with Primary Progressive Multiple Sclerosis - At least 18 years of age Exclusion Criteria: - Participants not willing to participate or sign informed consent

Additional Information

Official title Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
Principal investigator Simon Gr, PhD
Description Unlike Relapsing Remitting Multiple Sclerosis (RRMS) or Secondary Progressive Multiple Sclerosis (SPMS) in which patients experience a remission or lessening of their symptoms, Primary Progressive Multiple Sclerosis (PPMS) is characterized by progression of disability from onset, with no, or only occasional and minor, remissions and improvements. The age of onset for the primary progressive subtype is later than for the relapsing-remitting, but similar to mean the age of progression between the relapsing-remitting and the secondary progressive - around 40 years of age. Because of its prevalence, RRMS represents the largest basis for basic and clinical MS research. Therefore, drugs have primarily been developed to slow disease progression in RRMS and SPMS patients. No treatment has been proven successful in treating primary progressive MS. The MURDOCK-MS collection represents a unique opportunity to carry out detailed biomarker research on PPMS patients and, to the knowledge of this investigator and his colleagues in the field, would represent an exceptional cohort that is not available elsewhere in the US or the rest of the world. Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression. This progressive etiology would provide valuable insight into PPMS development and may also shed light on SPMS progression.
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Duke University.